Kazia Share Price, page-626

Based on current data in unmethylated GBM in terms of efficacy both compounds are indeterminate / non-inferior (the confidence intervals overlap) but in terms of safety VAL-083 is substantially worse than paxalisib (I wouldn’t bone marrow suppression, especially not when I already battle with cancer) and IV administration vs. oral administration also has an easy winner.

For methylated GBM the results did not look too stunning vs. historic controls. The verdict is still out for recurrent GBM for both compounds.

Throw some unfortunate timing for a capital raise in and you may have at least some level of explanation in this market environment.